Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. filed a Form 8-K reporting an event occurring on March 14, 2023. The filing concerns the termination of a material loan agreement and does not provide quarterly or annual operating results.
Key Financial and Capital Structure Information
| Item | Reported information |
|---|---|
| Debt agreement | Western Alliance Agreement, a collateralized term loan with aggregate principal capacity of up to $15 million |
| Payoff amount | Approximately $7.36 million |
| Payoff funding | Available cash on hand |
| Principal and interest paid | Approximately $7.02 million |
| Prepayment fee | $300,000, payable following prior FDA approval of an investigational new drug application |
| Other prepayment charges | $35,000, plus de minimis operational fees |
| Interest rate | Floating rate of 1.25% to 2.75% above the prime rate |
| Original maturity | October 30, 2023 |
The filing does not provide revenue, profit, cash flow, margin, or liquidity balances after the payoff.
Material Changes Versus the Prior Period
- On March 14, 2023, Arcturus paid off and terminated the Western Alliance Agreement before its scheduled October 30, 2023 maturity.
- The payoff reduced the company’s outstanding debt by approximately $7.02 million of principal and interest, based on the amount disclosed in the filing.
- Arcturus was released from all liens securing the agreement.
- Available cash was reduced by approximately $7.36 million, including fees and charges.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, or management commentary beyond the debt termination. The transaction represents a material use of cash and included a $300,000 prepayment fee and $35,000 in prepayment charges. The filing does not state whether replacement financing is planned or quantify the company’s remaining liquidity.
Important Facts for Investors to Verify
- Confirm the company’s cash and cash-equivalent balance after the approximately $7.36 million payoff.
- Review subsequent filings for replacement debt, additional financing, or changes in liquidity.
- Assess the effect of eliminating the Western Alliance loan on interest expense and secured obligations.
- Verify whether any other debt, liens, financial covenants, or contingent obligations remained outstanding.
- Review later financial statements for the accounting treatment of the prepayment fee and related charges.